Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors

BACKGROUND: While immune checkpoint inhibitors (ICIs) occasionally cause immune-related adverse events (irAEs) in various organs, the prevalence of irAEs and potential risk factors have not been clarified. We identified irAE predictive factors and examined the relationship between the effect of ICIs...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshikawa, Yuki, Imamura, Michio, Yamauchi, Masami, Hayes, C. Nelson, Aikata, Hiroshi, Okamoto, Wataru, Miyata, Yoshihiro, Okada, Morihito, Hattori, Noboru, Sugiyama, Kazuhiko, Yoshioka, Yukio, Toratani, Shigeaki, Takechi, Masaaki, Ichinohe, Tatsuo, Ueda, Tsutomu, Takeno, Sachio, Kobayashi, Tsuyoshi, Ohdan, Hideki, Teishima, Jun, Hide, Michihiro, Nagata, Yasushi, Kudo, Yoshiki, Iida, Koji, Chayama, Kazuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706984/
https://www.ncbi.nlm.nih.gov/pubmed/36447159
http://dx.doi.org/10.1186/s12885-022-10327-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706984/
https://www.ncbi.nlm.nih.gov/pubmed/36447159
http://dx.doi.org/10.1186/s12885-022-10327-7

Ejemplares similares